Turnstone Biologics Statistics
Total Valuation
TSBX has a market cap or net worth of $8.21 million. The enterprise value is -$8.06 million.
| Market Cap | 8.21M |
| Enterprise Value | -8.06M |
Important Dates
The last earnings date was Monday, August 18, 2025, after market close.
| Earnings Date | Aug 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSBX has 23.14 million shares outstanding. The number of shares has increased by 6.59% in one year.
| Current Share Class | 23.14M |
| Shares Outstanding | 23.14M |
| Shares Change (YoY) | +6.59% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 3.83% |
| Owned by Institutions (%) | 25.05% |
| Float | 19.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.33 |
| Quick Ratio | 2.63 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -126.71% and return on invested capital (ROIC) is -73.42%.
| Return on Equity (ROE) | -126.71% |
| Return on Assets (ROA) | -57.78% |
| Return on Invested Capital (ROIC) | -73.42% |
| Return on Capital Employed (ROCE) | -306.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.37M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TSBX has paid $33,000 in taxes.
| Income Tax | 33,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.60% in the last 52 weeks. The beta is 1.37, so TSBX's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -83.60% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.41 |
| Relative Strength Index (RSI) | 49.25 |
| Average Volume (20 Days) | 149,162 |
Short Selling Information
The latest short interest is 281,355, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 281,355 |
| Short Previous Month | 334,611 |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.41% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | -55.63M |
| Operating Income | -45.29M |
| Pretax Income | -75.09M |
| Net Income | -47.20M |
| EBITDA | -44.16M |
| EBIT | -45.29M |
| Earnings Per Share (EPS) | -$2.05 |
Balance Sheet
The company has $16.69 million in cash and $411,000 in debt, giving a net cash position of $16.28 million or $0.70 per share.
| Cash & Cash Equivalents | 16.69M |
| Total Debt | 411,000 |
| Net Cash | 16.28M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 14.76M |
| Book Value Per Share | 0.64 |
| Working Capital | 14.76M |
Cash Flow
In the last 12 months, operating cash flow was -$45.45 million and capital expenditures $20,000, giving a free cash flow of -$45.43 million.
| Operating Cash Flow | -45.45M |
| Capital Expenditures | 20,000 |
| Free Cash Flow | -45.43M |
| FCF Per Share | -$1.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.59% |
| Shareholder Yield | -6.59% |
| Earnings Yield | -574.56% |
| FCF Yield | -552.99% |
Analyst Forecast
The average price target for TSBX is $4.75, which is 1,238.03% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.75 |
| Price Target Difference | 1,238.03% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |